Skip to Content

Zelapar (selegiline) Disease Interactions

There are 8 disease interactions with Zelapar (selegiline):


Dopamine agonists (Includes Zelapar) ↔ hypotension

Severe Potential Hazard, Moderate plausibility. Applies to: Hypotension

Dopamine agonists may impair the systemic regulation of blood pressure, with resultant orthostatic hypotension, especially during dose escalation. Therapy with dopamine agonists should be monitored carefully in patients with Parkinson's disease since they may have an impaired ability to respond to an orthostatic challenge, and also in patients receiving antihypertensive drugs.


  1. "Product Information. Dostinex (cabergoline)." Pharmacia and Upjohn, Kalamazoo, MI.
  2. "Product Information. Sinemet CR (carbidopa-levodopa)." Dupont Pharmaceuticals, Wilmington, DE.
  3. Iwasaki S, Hamaguchi K, Iwasaki A, Takakusagi M, Narabayashi Y "Hypotensive effect of long-term levodopa in patients with Parkinson's disease." Eur Neurol 30 (1990): 194-9
  4. Hoehn MM "Levodopa-induced postural hypotension. Treatment with fludrocortisone." Arch Neurol 32 (1975): 50-1
  5. "Product Information. Mirapex (pramipexole)." Boehringer Ingelheim, Ridgefield, CT.
  6. "Product Information. Sinemet (carbidopa-levodopa)." DuPont Pharmaceuticals, Wilmington, DE.
View all 6 references

Selegiline (Includes Zelapar) ↔ major psychotic disorders

Severe Potential Hazard, Moderate plausibility. Applies to: Psychosis

Patients with major psychotic disorders should ordinarily not be treated with selegiline because of the risk of exacerbating psychosis.


Selegiline (Includes Zelapar) ↔ severe renal dysfunction

Severe Potential Hazard, Moderate plausibility. Applies to: Renal Dysfunction

Small increments in serum BUN and creatinine have been observed in patients treated with high dose of selegiline. Treatment with selegiline is not recommended in patients with severe renal impairment and end-stage renal disease (CrCl <30 mL/min).


Monoamine oxidase inhibitors (Includes Zelapar) ↔ hypotension

Moderate Potential Hazard, Moderate plausibility. Applies to: Hypotension

Hypotension has been observed during therapy with monoamine oxidase inhibitors. These drugs should be used with caution, especially in patients with tendency towards hypotension or taking other drugs known to cause hypotension.


Selegiline (Includes Zelapar) ↔ hypertension

Moderate Potential Hazard, Moderate plausibility. Applies to: Hypertension

Selegiline can cause hypertensive reactions and it should be used with caution in patients with hypertension. Patients should report any symptoms such as occipital headache, palpitations, neck stiffness or soreness, nausea, sweating, dilated pupils and photophobia. Patients receiving therapy need to have monitored their blood pressure frequently to detect any evidence of pressor response. Additionally, patients should be advised to avoid foods and drinks with high tyramine content such as cheese, sour cream, beer, liver, bananas and others, as these might trigger a hypertensive crisis.


Selegiline (Includes Zelapar) ↔ liver disease

Moderate Potential Hazard, Moderate plausibility. Applies to: Liver Disease

Patients with mild to moderate hepatic impairment (Child-Pugh 5 to 9), may require a dose reduction of selegiline depending on their clinical response. Selegiline is not recommended in patients with severe hepatic impairment (Child-Pugh >9).


Selegiline (Includes Zelapar) ↔ melanoma

Moderate Potential Hazard, Moderate plausibility. Applies to: Skin Cancer

Patients with Parkinson's disease have a higher risk of developing melanoma than the general population. Patients and providers should be advised to monitor for melanoma frequently and regularly when using selegiline. Skin examinations should be performed by qualified individuals (e.g., dermatologists).


Selegiline (Includes Zelapar) ↔ sleep disorders

Moderate Potential Hazard, Moderate plausibility. Applies to: Sleep Disorder

Selegiline should be used with caution in patients with sleep disorders as it can cause somnolence. Patients should exercise caution when driving, operating machines, or working at heights during treatment. Treatment should be discontinued if patients develop daytime sleepiness with episodes of falling asleep during activities such as conversation, eating, etc. If not discontinued, patients should be very cautious about the activities that they engage in that could be potentially dangerous. Prescribers should question the patients specifically about somnolence, as it is rarely reported by patients, and ask about sleep disorders and the use of concomitant sedating medications.

Zelapar (selegiline) drug interactions

There are 774 drug interactions with Zelapar (selegiline)

Zelapar (selegiline) alcohol/food interactions

There are 2 alcohol/food interactions with Zelapar (selegiline)

Drug Interaction Classification

These classifications are only a guideline. The relevance of a particular drug interaction to a specific individual is difficult to determine. Always consult your healthcare provider before starting or stopping any medication.
Major Highly clinically significant. Avoid combinations; the risk of the interaction outweighs the benefit.
Moderate Moderately clinically significant. Usually avoid combinations; use it only under special circumstances.
Minor Minimally clinically significant. Minimize risk; assess risk and consider an alternative drug, take steps to circumvent the interaction risk and/or institute a monitoring plan.
Unknown No interaction information available.

Further information

Always consult your healthcare provider to ensure the information displayed on this page applies to your personal circumstances.